Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Announces Completion of Enrollment in ENCORE-LF Phase 2b Clinical Trial of Emricasan in Patients with Decompensated NASH Cirrhosis
SAN DIEGO , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor.
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Publications Expanding on Previously Reported Results from Completed Phase 2 NAFLD-NASH, Portal Hypertension and Liver Cirrhosis Clinical Trials
SAN DIEGO , Jan. 28, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced publications expanding on previously reported results from three of the company’s completed Phase 2 clinical trials. Mitchell Schiffman , M.D., is the lead author on a new publication 1 in
View HTML
Toggle Summary Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
- Clinically Meaningful Improvements in Portal Hypertension in High Risk Compensated Cirrhosis Patients - - Conference Call and Webcast Presentation at 8:30 a.m. ET Today - SAN DIEGO , Dec. 05, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting
SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the schedule of upcoming oral presentations and posters addressing clinical and preclinical results with the company’s pan-caspase inhibitor emricasan, or addressing preclinical results with
View HTML
Toggle Summary Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates
SAN DIEGO , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and nine months ended September 30, 2018 ,
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results
SAN DIEGO , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the third quarter ended September 30, 2018 , after the market close on Thursday, November 1, 2018 . Conatus will host a conference call and audio
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting
SAN DIEGO , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that two abstracts – one addressing clinical results with the company’s pan-caspase inhibitor, emricasan, and one addressing preclinical results with the company’s pan-caspase inhibitor,
View HTML
Toggle Summary Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension
SAN DIEGO , Sept. 20, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, will host an invitation-only symposium on portal hypertension for institutional investors and research analysts on
View HTML
Toggle Summary Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted invitations to participate in two upcoming investor conferences. At the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease ( September 26-27 in New York ), senior management will
View HTML
Toggle Summary Conatus Pharmaceuticals to Present at BioCentury NewsMakers Conference
SAN DIEGO , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it has been invited to present at the BioCentury 25 th Annual NewsMakers
View HTML